July 23, 2020
Calciscon Announces Closing of Over-subscribed Pre-series A Financing
The proceeds of its CHF 600k pre-series A financing enables the company to initiate initial sales of its flagship product the T50 Calcification Propen...
June 06, 2020
Prospective Fresenius Study Confirms T50 as Independent Predictor of Mortality for Hemodialysis Patients
Fresenius Medical Care presented its T50 study of 776 hemodialysis patients at the European Nephrology (ERA-EDTA) Congress. The study confirms T50 as...
June 04, 2020
T50 Identified as New Independent Cardiovascular Risk Factor in the General Population
A research team from University Groningen (NL) led by Prof. H. van Goor and Prof. M. de Borst, identified T50 as a new cardiovascular risk factor in t...
February 01, 2020
INNOVATION AWARD 2020 for Rapid T50 Test
"The winner of this year's INNOVATION AWARD of RWTH Aachen University, Germany, was a research team led by Prof. Dr. Schomburg from the Institute of M...
December 01, 2019
Calciscon Announces Vincent Linder as CEO
The Board of Directors has appointed Vincent Linder as Chief Executive Officer (CEO). Dr. Pasch, co-founder and past-CEO, maintains his leadership rol...
© 2020 by CALCISCON |
Design by W4TW